Galmed Pharma (GLMD) Tops Q3 EPS by 19c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of $0.05, $0.19 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Alcoa prices $2.6B in senior notes to fund South32 asset deal
• Skillsoft (SKIL) Tops Q2 EPS by 14c; Offers Guidance